-
公开(公告)号:WO2023065478A1
公开(公告)日:2023-04-27
申请号:PCT/CN2021/135559
申请日:2021-12-04
Applicant: 广东金骏康生物技术有限公司
IPC: A61K31/7048 , A61K36/296 , A61P19/10 , C12N15/56 , C12N15/81 , C12N9/24 , A23L33/105
Abstract: 一种淫羊藿次苷Ⅰ的用途。试验表明,淫羊藿次苷Ⅰ可显著提高小鼠骨密度,促进成骨细胞形成,抑制破骨细胞的形成,使得淫羊藿次苷Ⅰ可应用在制备预防和/或治疗骨质疏松症的药物或保健品中。
-
2.
公开(公告)号:WO2023059687A1
公开(公告)日:2023-04-13
申请号:PCT/US2022/045737
申请日:2022-10-05
Applicant: WHISPERGENICS, INC.
Inventor: BRUNICARDI, Francis, Charles , SANCHEZ, Robbi, L.
IPC: A61K31/155 , A61K31/366 , A61K31/7048 , A61P35/00 , C12Q1/6886
Abstract: The present invention includes a method of inhibiting growth of cancer in a patient, the method comprising contacting the cancer with amounts of metformin or a metformin analog; at least one statin selected from the group consisting of: simvastatin, atorvastatin, rosuvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, and prosuvastatin; and a cardiac glycoside in an amount sufficient to inhibit the growth of the breast, colorectal, glioblastoma or prostate cancer.
-
3.
公开(公告)号:WO2023059362A1
公开(公告)日:2023-04-13
申请号:PCT/US2022/011251
申请日:2022-01-05
Applicant: AIPHARMA GLOBAL HOLDINGS LLC
Inventor: FREER, Carl Johan , KASZYNSKI, Richard , GADOTTI, Alessandro
IPC: A61K31/135 , A61K31/4965 , A61K31/7048 , A61K31/706 , A61K31/7068 , A61P31/14
Abstract: A method for treating an early-stage microbial infection comprising determining whether a subject exposed to a coronavirus, such as SARS-CoV-2, or suspected of being exposed to a microbe, or exposed to another infected with or suspected of being infected with a coronavirus and, if the subject is infected with the coronavirus, administering an antimicrobial agent is provided herein.
-
公开(公告)号:WO2023047413A1
公开(公告)日:2023-03-30
申请号:PCT/IN2022/050842
申请日:2022-09-21
Applicant: GODAVARI BIOREFINERIES LIMITED
Inventor: REDASANI, Vijayendra , GAVADE, Sandip , ATHAVALE, Maithili , KHARKAR, Prashant
IPC: A61K9/20 , A61K9/16 , A61K47/32 , A61K47/36 , A61K31/36 , A61K31/4025 , A61K31/7048 , A61P35/00
Abstract: The present invention relates to pharmaceutical compositions comprising compound of Formula IV, along with a solubilizing agent and a process to prepare the same. The said pharmaceutical compositions have enormous applications in cancer therapy. The present invention has come up with a novel and innovative pharmaceutical composition for the compounds of Formula IV that show significant stability as well as the desired bioavailability on drug release.
-
公开(公告)号:WO2023038413A1
公开(公告)日:2023-03-16
申请号:PCT/KR2022/013402
申请日:2022-09-07
Applicant: 주식회사 제넨셀
IPC: A61K36/185 , A61K31/7048 , A61K31/7034 , A61K31/352 , A61P31/16 , A23L33/105 , A61K8/9789 , A61K8/60 , A61Q17/00
Abstract: 본 발명의 목적은 담팔수 추출물(Elaeocarpus sylvestris), 분획물 또는 이들 유래 페놀화합물을 유효성분으로 포함하는, 인플루엔자 바이러스 감염증 예방, 치료용 약학적 조성물을 제공하는 것이다.
-
6.
公开(公告)号:WO2023022672A2
公开(公告)日:2023-02-23
申请号:PCT/TR2021/050827
申请日:2021-08-18
Applicant: ARVEN ILAC SANAYI VE TICARET ANONIM SIRKETI
Inventor: CELIK, Devrim , YILMAZ, Emine , EKRAM, Yelda , TASKIN, Gokce Canan
IPC: A61K31/7048 , A61K9/10 , A61K9/00
Abstract: The invention relates to a simple, rapid, cost effective, time-saving and industrially convenient process for the preparation of suspensions to be used in pharmaceutical formulations comprising ivermectin as an active agent for inhalation by nebulization. Further, the present invention also relates to inhalation compositions comprising ivermectin, isotonic agents, buffering agents, dispersing or suspending agents.
-
公开(公告)号:WO2023003193A1
公开(公告)日:2023-01-26
申请号:PCT/KR2022/009127
申请日:2022-06-27
Applicant: 중앙대학교 산학협력단
IPC: A61K31/7048 , A61K36/65 , A61P21/00 , A23L33/125
Abstract: 본 발명은 페오니플로린을 포함하는 악액질 및 근손실 예방 또는 치료용 약학적 조성물에 관한 것이다. 페오니플로린을 포함하는 약학적 조성물을 이용하면 악액질 및 근손실을 효과적으로 예방 또는 치료할 수 있다.
-
公开(公告)号:WO2023279315A1
公开(公告)日:2023-01-12
申请号:PCT/CN2021/105138
申请日:2021-07-08
Applicant: 中国科学院深圳先进技术研究院
IPC: A61K31/7048 , A61K36/296 , A61K135/00 , A61P21/00
Abstract: 本发明提供了鼠李糖基淫羊藿次苷II在制备肌肉修复和再生药物中的应用,具体提供了鼠李糖基淫羊藿次苷II在制备用于治疗或预防肌肉疾病、促进肌肉修复或促进肌肉再生的药物或试剂中的应用,所述肌肉损伤为创伤性肌肉损伤或非创伤性肌肉损伤。所述非创伤性肌肉损伤选自肌源性肌肉萎缩、废用性肌肉萎缩、肌肉营养不良、肌肉减少症、肌肉病变、肌无力。本发明首次证明了鼠李糖基淫羊藿次苷II在促进肌细胞增殖或分化、提高肌管数量、促进肌管形成、提高肌管长度、提高肌管宽度、促进成肌细胞分化或促进肌细胞融合等方面的作用。
-
公开(公告)号:WO2023276811A1
公开(公告)日:2023-01-05
申请号:PCT/JP2022/024859
申请日:2022-06-22
Applicant: 東洋精糖株式会社
Inventor: 中西 章仁 , タンジャ マハマドゥ
IPC: A61K31/7048 , A61P31/14 , C07K14/165 , C12N15/50
Abstract: 本発明は、ウイルスの細胞への侵入を阻害する、ウイルスの細胞侵入阻害剤を提供することを課題とする。 本発明は、α-グルコシルルチン、α-グルコシルヘスペリジンおよびα-グルコシルナリンジンから選択される少なくとも一種の成分(A)を含む、ウイルスの細胞侵入阻害剤であって、前記ウイルスがアンギオテンシン変換酵素2(ACE2)と結合するスパイクタンパク質を有する、ウイルスの細胞侵入阻害剤を含む。
-
公开(公告)号:WO2022251597A1
公开(公告)日:2022-12-01
申请号:PCT/US2022/031293
申请日:2022-05-27
Applicant: VERGE ANALYTICS, INC.
Inventor: NIELAND, Thomas J.F. , HANSON-SMITH, Victor , CHOI, Irene Y.
IPC: A61K31/416 , A61K31/423 , A61K31/473 , A61K31/496 , A61K31/4985 , A61K31/519 , A61K31/5377 , A61K31/551 , A61K31/7048 , A61K31/7105 , A61K31/713 , A61K38/00 , A61P25/28
Abstract: The present disclosure relates to methods for treating a neurological disorder such as Parkinson's Disease (PD) and Alzheimer's Disease. The method may comprise administering to a subject in need thereof an effective amount of an agent that modulates RSK1 and/or RSK2.
-
-
-
-
-
-
-
-
-